Highlights Venus Remedies Limited

Stocks

526953

INE411B01019

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:19:55 11/06/2026 BST			5-day change	1st Jan Change
1,716.45 ^INR	+5.00%		+15.59%	+123.79%

10:38am	India allows regulator to raise cancer drug prices to tackle shortage	RE
06-09	Indian cancer patients battle shortage of key drugs as platinum costs surge	RE

Highlights

05-26	Venus Remedies Limited announces Annual dividend, payable on September 19, 2026	CI
05-26	Venus Remedies Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
05-22	Venus Remedies receives Saudi FDA approval for plerixafor	RE
01-29	Venus Remedies Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
12-08	Venus Remedies receives final 110 mln rupees payment from Cipla	RE
11-10	Venus Remedies Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
01/08/25	Venus Remedies Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
26/05/25	Venus Remedies Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	CI
22/05/25	Venus Remedies Renews GMP Certification from Ukraine's Regulator for Baddi, India Unit	MT
17/04/25	Venus Remedies Gets US FDA's QIDP Designation for its Novel Antibiotic Formulation; Shares Up 8%	MT
17/04/25	Venus Remedies Says US FDA Grants QIDP Designation To Venus Remedies' VRP-034	RE
17/04/25	US FDA Grants Qualified Infectious Disease Product Designation to Venus Remedies's VRP-034	CI
26/03/25	AdjuTec Pharma Launches a Research Collaboration with Venus Remedies Limited	CI
25/02/25	Infex Therapeutics Holdings Limited Signs a License Agreement for the Indian Market with Venus Remedies Ltd	CI
25/02/25	Venus Remedies Secures In-Licensing Rights to Develop, Commercialize MET-X in India	MT
05/02/25	Venus Remedies' Consolidated Profit Jumps in Fiscal Q3	MT
04/02/25	Venus Remedies Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	CI
05/11/24	Venus Remedies' Syringe Facility Gets GMP Accreditation from Malaysia	MT
29/10/24	Venus Remedies Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	CI
13/08/24	Venus Remedies Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	CI
13/06/24	Venus Remedies Bags Tender from UNICEF for Antibiotic Ceftriaxone	MT
30/05/24	Venus Remedies Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
19/03/24	Venus Remedies Secures Marketing Authorizations in Ukraine for Three Oncology Drugs	MT
08/03/24	Venus Remedies Gets Ukraine's Marketing Approval for Three Oncology Products	MT
14/02/24	Venus Remedies Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI